Symbols / ORMP
ORMP Chart
About
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 141.86M |
| Enterprise Value | 2.94M | Income | 43.85M | Sales | 2.00M |
| Book/sh | 4.98 | Cash/sh | 3.38 | Dividend Yield | 7.24% |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 3.56 | Forward P/E | -44.50 | PEG | — |
| P/S | 70.93 | P/B | 0.72 | P/C | — |
| EV/EBITDA | -0.23 | EV/Sales | 1.47 | Quick Ratio | 22.08 |
| Current Ratio | 22.25 | Debt/Eq | 0.42 | LT Debt/Eq | — |
| EPS (ttm) | 1.00 | EPS next Y | -0.08 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -4.22% |
| ROE | 24.48% | ROIC | — | Gross Margin | 0.65% |
| Oper. Margin | -6.51% | Profit Margin | 21.93% | Shs Outstand | 39.80M |
| Shs Float | 29.16M | Short Float | 1.87% | Short Ratio | 2.08 |
| Short Interest | — | 52W High | 3.71 | 52W Low | 1.82 |
| Beta | 1.31 | Avg Volume | 220.60K | Volume | 86.18K |
| Target Price | $3.25 | Recom | None | Prev Close | $3.46 |
| Price | $3.56 | Change | 2.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.25
Mean price target
2. Current target
$3.56
Latest analyst target
3. DCF / Fair value
$-1.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.56
Low
$3.25
High
$3.25
Mean
$3.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-09-09 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-05-20 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-05-17 | main | Canaccord Genuity | Hold → Hold | $2 |
| 2023-01-17 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2023-01-12 | down | Canaccord Genuity | Buy → Hold | — |
| 2022-05-16 | main | Aegis Capital | — → Buy | $30 |
| 2022-02-18 | init | Cantor Fitzgerald | — → Overweight | $20 |
| 2021-11-30 | main | HC Wainwright & Co. | — → Buy | $32 |
| 2021-11-29 | main | HC Wainwright & Co. | — → Buy | $32 |
| 2021-11-02 | main | Aegis Capital | — → Buy | $35 |
| 2021-07-29 | main | Canaccord Genuity | — → Buy | $30 |
| 2021-06-08 | main | Aegis Capital | — → Buy | $20 |
| 2021-04-20 | init | Canaccord Genuity | — → Buy | $27 |
| 2021-02-09 | init | National Securities Corporation | — → Buy | $23 |
| 2021-01-27 | main | Aegis Capital | — → Buy | $12 |
| 2020-07-13 | reit | HC Wainwright & Co. | — → Buy | $17 |
| 2020-06-22 | main | HC Wainwright & Co. | — → Buy | $16 |
| 2019-09-11 | init | Ladenburg Thalmann | — → Buy | $7 |
| 2015-11-19 | init | FBR Capital | — → Outperform | $15 |
| 2015-10-01 | init | HC Wainwright & Co. | — → Buy | $24 |
- ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS - PR Newswire Mon, 17 Nov 2025 08
- This small drug maker turned $99.5M into $118M—and pays out - Stock Titan Wed, 07 Jan 2026 08
- ORMP: Advancing Clinical Activities, Generating Gains From Investment Portfolio, New Rights Plan Adopted - Yahoo Finance Mon, 24 Nov 2025 08
- Oramed Pharmaceuticals Restructures Scilex Notes via Warrant Deal - TipRanks Fri, 20 Feb 2026 21
- Can Oramed Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis Fri, 19 Dec 2025 08
- Oramed Reports Fiscal Third Quarter 2025 Financial Results - PR Newswire Mon, 17 Nov 2025 08
- Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential - simplywall.st Fri, 21 Nov 2025 08
- Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback - Seeking Alpha Wed, 24 Dec 2025 08
- Oramed Pharm Announces Dividend After Scilex Payment Gain - The Globe and Mail hu, 08 Jan 2026 08
- The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance Sat, 17 May 2025 07
- Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation - simplywall.st hu, 13 Nov 2025 08
- Oramed (NASDAQ: ORMP) posts $210M assets, plans one-time dividend; U.S. insulin trial - Stock Titan hu, 23 Oct 2025 07
- There Are Some Holes In Oramed Pharmaceuticals' (NASDAQ:ORMP) Solid Earnings Release - Yahoo Finance Fri, 21 Nov 2025 08
- Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical - PR Newswire Mon, 28 Apr 2025 07
- Oramed Pharmaceuticals And 2 Other Promising Penny Stocks To Watch - Yahoo Finance ue, 16 Dec 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 109000 | — | — | KIDRON NADAV | Chief Executive Officer | — | 2026-01-22 00:00:00 | D | nan |
| 1 | 19000 | — | — | KIDRON MIRIAM | Officer and Director | — | 2026-01-22 00:00:00 | D | nan |
| 2 | 19000 | — | — | HEXTER JOSHUA | Chief Operating Officer | — | 2026-01-22 00:00:00 | D | nan |
| 3 | 19000 | — | — | GABAY AVRAHAM | Chief Financial Officer | — | 2026-01-22 00:00:00 | D | nan |
| 4 | 86166 | — | Stock Gift at price 0.00 per share. | KIDRON MIRIAM | Officer and Director | — | 2026-01-14 00:00:00 | D | — |
| 5 | 212328 | — | Stock Award(Grant) at price 0.00 per share. | HEXTER JOSHUA | Chief Operating Officer | — | 2025-12-31 00:00:00 | D | — |
| 6 | 196216 | — | Stock Award(Grant) at price 0.00 per share. | GABAY AVRAHAM | Chief Financial Officer | — | 2025-12-31 00:00:00 | D | — |
| 7 | 34900 | — | Stock Award(Grant) at price 0.00 per share. | MAYER ARIE PH.D. | Director | — | 2025-12-31 00:00:00 | D | — |
| 8 | 33500 | — | Stock Award(Grant) at price 0.00 per share. | SHAPIRO BENJAMIN | Director | — | 2025-12-31 00:00:00 | D | — |
| 9 | 36250 | — | Stock Award(Grant) at price 0.00 per share. | AGHION DANIEL | Director | — | 2025-12-31 00:00:00 | D | — |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-08-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.52M | 0.00 | -132.30K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -7.63M | -8.95M | -36.98M | -25.04M |
| TotalUnusualItems | -7.24M | 16.27M | -630.00K | 893.00K |
| TotalUnusualItemsExcludingGoodwill | -7.24M | 16.27M | -630.00K | 893.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -19.06M | 5.53M | -36.56M | -22.24M |
| ReconciledDepreciation | 193.00K | 196.00K | 58.00K | 77.00K |
| EBITDA | -14.87M | 7.32M | -37.61M | -24.15M |
| EBIT | -15.07M | 7.12M | -37.66M | -24.22M |
| NetInterestIncome | 4.10M | 4.59M | 3.56M | 341.00K |
| InterestExpense | 853.00K | 2.04M | 0.00 | |
| InterestIncome | 5.00M | 8.17M | 3.57M | 347.00K |
| NormalizedIncome | -13.34M | -10.74M | -36.06M | -23.13M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -19.06M | 5.53M | -36.56M | -22.24M |
| TotalExpenses | 12.78M | 17.11M | 43.30M | 26.93M |
| TotalOperatingIncomeAsReported | -12.78M | -15.77M | -40.60M | -24.22M |
| DilutedAverageShares | 40.83M | 40.57M | 39.00M | 28.47M |
| BasicAverageShares | 40.83M | 40.32M | 39.00M | 28.47M |
| DilutedEPS | -0.48 | 0.14 | -0.94 | -0.78 |
| BasicEPS | -0.48 | 0.14 | -0.94 | -0.78 |
| DilutedNIAvailtoComStockholders | -19.06M | 5.53M | -36.56M | -22.24M |
| NetIncomeCommonStockholders | -19.06M | 5.53M | -36.56M | -22.24M |
| NetIncome | -19.06M | 5.53M | -36.56M | -22.24M |
| MinorityInterests | 43.00K | 437.00K | 1.20M | 751.00K |
| NetIncomeIncludingNoncontrollingInterests | -19.10M | 5.09M | -37.76M | -22.99M |
| NetIncomeContinuousOperations | -19.10M | 5.09M | -37.76M | -22.99M |
| TaxProvision | 3.18M | 0.00 | 100.00K | |
| PretaxIncome | -15.92M | 5.09M | -37.66M | -22.99M |
| OtherIncomeExpense | -7.24M | 16.27M | -630.00K | 893.00K |
| GainOnSaleOfSecurity | -7.24M | 16.27M | -630.00K | 893.00K |
| NetNonOperatingInterestIncomeExpense | 4.10M | 4.59M | 3.56M | 341.00K |
| TotalOtherFinanceCost | 42.00K | 1.54M | 9.00K | 6.00K |
| InterestExpenseNonOperating | 853.00K | 2.04M | 0.00 | |
| InterestIncomeNonOperating | 5.00M | 8.17M | 3.57M | 347.00K |
| OperatingIncome | -12.78M | -15.77M | -40.60M | -24.22M |
| OperatingExpense | 12.78M | 17.11M | 43.30M | 26.93M |
| ResearchAndDevelopment | 6.32M | 8.97M | 27.64M | 20.99M |
| SellingGeneralAndAdministration | 6.46M | 8.14M | 15.66M | 5.94M |
| SellingAndMarketingExpense | 0.00 | -287.00K | 1.85M | |
| GeneralAndAdministrativeExpense | 6.46M | 8.43M | 13.81M | 5.94M |
| OtherGandA | 6.46M | 8.43M | 13.81M | 5.94M |
| TotalRevenue | 0.00 | 1.34M | 2.70M | 2.70M |
| OperatingRevenue | 0.00 | 1.34M | 2.70M | 2.70M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 39.92M | 40.34M | 39.56M | 35.29M |
| ShareIssued | 39.92M | 40.34M | 39.56M | 35.29M |
| NetDebt | 41.96M | |||
| TotalDebt | 372.00K | 51.62M | 894.00K | 533.00K |
| TangibleBookValue | 146.26M | 163.82M | 151.81M | 115.77M |
| InvestedCapital | 146.26M | 214.83M | 151.81M | 115.77M |
| WorkingCapital | 137.54M | 109.37M | 151.36M | 88.66M |
| NetTangibleAssets | 146.26M | 163.82M | 151.81M | 115.77M |
| CapitalLeaseObligations | 372.00K | 609.00K | 894.00K | 533.00K |
| CommonStockEquity | 146.26M | 163.82M | 151.81M | 115.77M |
| TotalCapitalization | 146.26M | 163.82M | 151.81M | 115.77M |
| TotalEquityGrossMinorityInterest | 145.35M | 162.89M | 151.16M | 116.52M |
| MinorityInterest | -918.00K | -928.00K | -656.00K | 744.00K |
| StockholdersEquity | 146.26M | 163.82M | 151.81M | 115.77M |
| RetainedEarnings | -176.62M | -157.56M | -163.08M | -114.85M |
| AdditionalPaidInCapital | 322.40M | 320.89M | 314.42M | 230.20M |
| CapitalStock | 480.00K | 485.00K | 476.00K | 424.00K |
| CommonStock | 480.00K | 485.00K | 476.00K | 424.00K |
| TotalLiabilitiesNetMinorityInterest | 9.93M | 57.66M | 10.49M | 11.48M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.25M | 4.44M | 4.74M | 4.80M |
| OtherNonCurrentLiabilities | 60.00K | 63.00K | 61.00K | 124.00K |
| EmployeeBenefits | 30.00K | 28.00K | 21.00K | 21.00K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 30.00K | 28.00K | 21.00K | 21.00K |
| NonCurrentDeferredLiabilities | 4.00M | 4.01M | 4.01M | 4.25M |
| NonCurrentDeferredRevenue | 4.00M | 4.00M | 4.00M | 4.24M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 11.00K | 11.00K | 11.00K |
| LongTermDebtAndCapitalLeaseObligation | 156.00K | 342.00K | 647.00K | 403.00K |
| LongTermCapitalLeaseObligation | 156.00K | 342.00K | 647.00K | 403.00K |
| CurrentLiabilities | 5.68M | 53.21M | 5.75M | 6.68M |
| CurrentDeferredLiabilities | 0.00 | 1.34M | 2.70M | |
| CurrentDeferredRevenue | 0.00 | 1.34M | 2.70M | |
| CurrentDebtAndCapitalLeaseObligation | 216.00K | 51.28M | 247.00K | 130.00K |
| CurrentCapitalLeaseObligation | 216.00K | 267.00K | 247.00K | 130.00K |
| CurrentDebt | 51.01M | |||
| LineOfCredit | 0.00 | 51.01M | 0.00 | |
| PayablesAndAccruedExpenses | 5.47M | 1.93M | 4.16M | 3.85M |
| CurrentAccruedExpenses | 1.15M | 1.06M | 1.98M | 1.19M |
| Payables | 4.32M | 876.00K | 2.18M | 2.66M |
| DuetoRelatedPartiesCurrent | 329.00K | 325.00K | 1.00K | 54.00K |
| TotalTaxPayable | 3.20M | 0.00 | ||
| IncomeTaxPayable | 3.20M | 0.00 | ||
| AccountsPayable | 789.00K | 551.00K | 2.17M | 2.61M |
| TotalAssets | 155.28M | 220.55M | 161.64M | 128.00M |
| TotalNonCurrentAssets | 12.06M | 57.97M | 4.53M | 32.66M |
| DefinedPensionBenefit | 32.00K | 27.00K | 24.00K | 24.00K |
| NonCurrentPrepaidAssets | 2.00K | 7.00K | 7.00K | 25.01M |
| FinancialAssets | 0.00 | 1.44M | 0.00 | |
| InvestmentsAndAdvances | 10.91M | 54.93M | 2.70M | 6.69M |
| OtherInvestments | 51.03M | 0.00 | ||
| InvestmentinFinancialAssets | 10.91M | 54.93M | 2.70M | 6.69M |
| HeldToMaturitySecurities | 0.00 | 6.69M | ||
| AvailableForSaleSecurities | 10.91M | 54.56M | 2.70M | |
| TradingSecurities | 0.00 | 367.00K | ||
| NetPPE | 1.11M | 1.57M | 1.80M | 932.00K |
| GrossPPE | 1.11M | 1.57M | 1.80M | 932.00K |
| OtherProperties | 1.11M | 1.57M | 1.80M | 397.00K |
| MachineryFurnitureEquipment | 7.00K | 535.00K | ||
| CurrentAssets | 143.22M | 162.58M | 157.11M | 95.34M |
| OtherCurrentAssets | 1.29M | 537.00K | 1.39M | 1.20M |
| PrepaidAssets | 1.20M | |||
| CashCashEquivalentsAndShortTermInvestments | 141.93M | 162.05M | 155.72M | 94.14M |
| OtherShortTermInvestments | 87.51M | 152.99M | 115.26M | 16.89M |
| CashAndCashEquivalents | 54.42M | 9.05M | 40.46M | 77.25M |
| CashFinancial | 9.05M | 40.46M | 77.25M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-08-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.43M | -10.55M | -28.41M | -21.56M |
| RepurchaseOfCapitalStock | -2.48M | 0.00 | ||
| RepaymentOfDebt | -49.55M | -50.00M | 0.00 | |
| IssuanceOfDebt | 0.00 | 99.55M | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 2.43M | 11.50M | 79.98M |
| CapitalExpenditure | -18.00K | -254.00K | -496.00K | -375.00K |
| InterestPaidSupplementalData | 2.32M | 574.00K | 0.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 100.00K | ||
| EndCashPosition | 54.42M | 9.05M | 40.46M | 77.25M |
| BeginningCashPosition | 9.05M | 40.46M | 27.46M | 19.30M |
| EffectOfExchangeRateChanges | -4.00K | -54.00K | -64.00K | 2.00K |
| ChangesInCash | 45.37M | -31.36M | 13.07M | 57.95M |
| FinancingCashFlow | -52.04M | 51.98M | 10.78M | 102.89M |
| CashFlowFromContinuingFinancingActivities | -52.04M | 51.98M | 10.78M | 102.89M |
| NetOtherFinancingCharges | -2.00K | -783.00K | 1.50M | |
| ProceedsFromStockOptionExercised | 0.00 | 62.00K | 21.41M | |
| NetCommonStockIssuance | -2.48M | 2.43M | 11.50M | 79.98M |
| CommonStockPayments | -2.48M | 0.00 | ||
| CommonStockIssuance | 0.00 | 2.43M | 11.50M | 79.98M |
| NetIssuancePaymentsOfDebt | -49.55M | 49.55M | 0.00 | |
| NetShortTermDebtIssuance | -49.55M | -50.00M | 0.00 | |
| ShortTermDebtPayments | -49.55M | -50.00M | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 99.55M | 0.00 | |
| LongTermDebtPayments | -50.00M | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 99.55M | 0.00 | |
| InvestingCashFlow | 105.82M | -73.04M | 30.21M | -23.76M |
| CashFlowFromContinuingInvestingActivities | 105.82M | -73.04M | 30.21M | -23.76M |
| NetOtherInvestingChanges | -65.00K | 2.00K | -1.00K | |
| NetInvestmentPurchaseAndSale | 105.90M | -72.78M | 30.68M | -23.39M |
| SaleOfInvestment | 161.66M | 118.14M | 185.09M | 30.43M |
| PurchaseOfInvestment | -55.76M | -190.92M | -154.41M | -53.82M |
| NetPPEPurchaseAndSale | -18.00K | -254.00K | -472.00K | -375.00K |
| SaleOfPPE | 0.00 | 24.00K | ||
| PurchaseOfPPE | -18.00K | -254.00K | -496.00K | -375.00K |
| OperatingCashFlow | -8.41M | -10.29M | -27.92M | -21.18M |
| CashFlowFromContinuingOperatingActivities | -8.41M | -10.29M | -27.92M | -21.18M |
| ChangeInWorkingCapital | 3.20M | -2.70M | -943.00K | -1.31M |
| ChangeInOtherWorkingCapital | 45.00K | -1.32M | -797.00K | -2.70M |
| ChangeInOtherCurrentLiabilities | -14.00K | 2.00K | -38.00K | -89.00K |
| ChangeInPayablesAndAccruedExpense | 3.52M | -2.23M | -376.00K | 2.06M |
| ChangeInPayable | 3.52M | -2.23M | -376.00K | 2.06M |
| ChangeInAccountPayable | 3.52M | -2.23M | -376.00K | 2.06M |
| ChangeInPrepaidAssets | -356.00K | 852.00K | 268.00K | -586.00K |
| OtherNonCashItems | -1.46M | 1.47M | 22.00K | 1.04M |
| StockBasedCompensation | 4.05M | 4.21M | 11.51M | 2.69M |
| UnrealizedGainLossOnInvestmentSecurities | 7.41M | -16.39M | 763.00K | -876.00K |
| DepreciationAmortizationDepletion | 193.00K | 196.00K | 58.00K | 77.00K |
| DepreciationAndAmortization | 193.00K | 196.00K | 58.00K | 77.00K |
| Depreciation | 193.00K | 196.00K | 58.00K | 77.00K |
| OperatingGainsLosses | -2.71M | -2.17M | -1.56M | 187.00K |
| PensionAndEmployeeBenefitExpense | -5.00K | -3.00K | 0.00 | |
| NetForeignCurrencyExchangeGainLoss | -2.70M | -2.17M | -1.55M | 187.00K |
| GainLossOnSaleOfPPE | 0.00 | -13.00K | ||
| NetIncomeFromContinuingOperations | -19.10M | 5.09M | -37.76M | -22.99M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ORMP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|